205 related articles for article (PubMed ID: 19237078)
1. Interferon (IFN) for malignant melanoma unmasking an autoimmune hepatitis.
Lebiedz P; August C; Domschke W; Schmidt HH
Eur J Intern Med; 2009 Jan; 20(1):e3-4. PubMed ID: 19237078
[No Abstract] [Full Text] [Related]
2. Adjuvant interferon in melanoma - a resurrection?
Middleton MR; Thatcher N
Br J Cancer; 2001 May; 84(9):1141-2. PubMed ID: 11336461
[No Abstract] [Full Text] [Related]
3. A potential predictive marker for response to interferon in malignant melanoma.
Wild PJ; Meyer S; Landthaler M; Hofstaedter F; Bosserhoff AK
J Dtsch Dermatol Ges; 2007 Jun; 5(6):456-9. PubMed ID: 17537037
[TBL] [Abstract][Full Text] [Related]
4. [Adjuvant interferon treatment of melanoma].
Török L
Magy Onkol; 2003; 47(1):105-7. PubMed ID: 12704462
[TBL] [Abstract][Full Text] [Related]
5. [Conclude that clinical trials on the overall effectiveness of interferon? Contribution of recent data].
Boulinguez S; Grange F
Ann Dermatol Venereol; 2011 May; 138(5 Suppl 1):H21-4. PubMed ID: 21703461
[No Abstract] [Full Text] [Related]
6. How melanoma is treated in real life.
Dummer R; Schadendorf D
Arch Dermatol; 2008 May; 144(5):664-5. PubMed ID: 18490596
[No Abstract] [Full Text] [Related]
7. [Adjuvant interferon therapy in malignant melanoma].
Mohr P
J Dtsch Dermatol Ges; 2007 Jun; 5(6):543-5. PubMed ID: 17537052
[No Abstract] [Full Text] [Related]
8. High-dose interferon and the U.K. guidelines for cutaneous melanoma.
Russell-Jones R; Healy C; Calonje E; Doherty M; Acland K
Br J Dermatol; 2002 Oct; 147(4):832-4; author reply 834-5. PubMed ID: 12366454
[No Abstract] [Full Text] [Related]
9. Treating patients with melanoma with interferon.
Cook J; Zitelli JA
Arch Dermatol; 1997 Mar; 133(3):387-9. PubMed ID: 9080905
[No Abstract] [Full Text] [Related]
10. [Testing of individual sensitivity to drugs in human malignant melanoma].
Czownicki Z
Pol Tyg Lek; 1988 Dec; 43(50):1627-30. PubMed ID: 3256805
[No Abstract] [Full Text] [Related]
11. Mucosal melanoma.
Seigler HF
J Surg Oncol; 2004 Jul; 86(4):187-8. PubMed ID: 15221925
[No Abstract] [Full Text] [Related]
12. Diverging opinions on interferon therapy for melanoma.
Winn RJ
J Natl Compr Canc Netw; 2004 Jan; 2(1):1. PubMed ID: 19777689
[No Abstract] [Full Text] [Related]
13. [Malignant melanoma: local perfusions].
Pettavel J
Pathol Biol (Paris); 1990 Oct; 38(8):870-1. PubMed ID: 2274394
[No Abstract] [Full Text] [Related]
14. How to manage melanoma in a psoriatic patient.
Papadavid E; Psyrri A; Pectasides D; Katoulis A; Balamoti E; Dalamaga M; Stavrianeas N
Dermatology; 2008; 216(3):277-8. PubMed ID: 18196939
[No Abstract] [Full Text] [Related]
15. Chemotherapy, cytokines, and biochemotherapy for melanoma.
Eton O
Cancer Chemother Biol Response Modif; 2005; 22():739-48. PubMed ID: 16110637
[No Abstract] [Full Text] [Related]
16. [Chemotherapy of malignant melanoma].
Jacquillat C; Auclerc G; Weil M; Israël L; Banzet P
Rev Prat; 1975 Nov; 25(51):4057-9. PubMed ID: 1209146
[No Abstract] [Full Text] [Related]
17. Adjuvant high-dose interferon therapy for high-risk melanoma.
Ready N; Weinstock MA
Arch Dermatol; 2003 Dec; 139(12):1635-7. PubMed ID: 14676083
[No Abstract] [Full Text] [Related]
18. High-dose interferon versus GM2 vaccine in high-risk malignant melanoma.
Wilson K
J Clin Oncol; 2001 Dec; 19(23):4350. PubMed ID: 11731522
[No Abstract] [Full Text] [Related]
19. [Anti-oncogram-assisted treatment planning in malignant melanoma].
Metelmann HR; Von Hoff D
Fortschr Kiefer Gesichtschir; 1988; 33():168-70. PubMed ID: 3165923
[No Abstract] [Full Text] [Related]
20. Persistent thrombocytopenia during melanoma treatment with fotemustine.
Turrisi G; Sozzi P; Marinozzi C; Clerico MA
Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
